|
ISCA1P1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.47739598332919E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
1.083530E-02 |
| Stage1-vs-Stage3 |
1.666790E-01 |
| Stage1-vs-Stage4 |
2.48579999995169E-06 |
| Stage2-vs-Stage3 |
2.742200E-03 |
| Stage2-vs-Stage4 |
1.87860000000484E-06 |
| Stage3-vs-Stage4 |
4.578400E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.70099490048869E-11 |
| Normal-vs-Asian |
1.62436730732907E-12 |
| Caucasian-vs-AfricanAmerican |
6.811600E-01 |
| Caucasian-vs-Asian |
6.711800E-01 |
| AfricanAmerican-vs-Asian |
9.012200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.720600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
8.9861999996721E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.751000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.704000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.587800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.506600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.739400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.679200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.026330E-04 |
| Classical-VS-Follicular |
1.821690E-02 |
| Classical-VS-Other |
8.372200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.04489999996904E-06 |
| Tall-VS-Other |
3.252400E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.679800E-01 |
| Follicular-VS-Normal |
1.62592161956354E-12 |
| Other-VS-Normal |
4.01679999995075E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.181800E-03 |
|
|
